News
ABVC
0.5812
+3.97%
0.0222
Weekly Report: what happened at ABVC last week (1223-1227)?
Weekly Report · 5h ago
Weekly Report: what happened at ABVC last week (1216-1220)?
Weekly Report · 12/23 11:04
ABVC BioPharma believes ABV-1504 can fill void in market after Prozac
TipRanks · 12/19 13:35
ABVC BioPharma Seeks To Revolutionize Mental Health Treatment With A Safe Prozac Alternative, Boasting A MADRS Score Reduction Of -13.21 From Baseline Over 6 Weeks With A Placebo-subtracted Difference Of -4.1
Benzinga · 12/19 13:34
Weekly Report: what happened at ABVC last week (1209-1213)?
Weekly Report · 12/16 11:05
ABVC BioPharma Receives $200,000 Payment from OncoX BioPharma as Part of Strategic Licensing Agreement
Barchart · 12/11 15:46
ABVC BioPharma gets $200K in cash from OncoX BioPharma
Seeking Alpha · 12/11 12:16
ABVC BioPharma receives $200,000 cash payment from OncoX
TipRanks · 12/11 11:40
ABVC BioPharma Reveals Receipt Of $200K Cash Payment From OncoX BioPharma As Part Of Its Strategic Licensing Agreement For Certain Oncology-related Products
Benzinga · 12/11 11:32
ABVC BIOPHARMA INC - RECEIVES $200,000 PAYMENT FROM ONCOX BIOPHARMA
Reuters · 12/11 11:30
ABVC BIOPHARMA SECURES $200,000 IN FIRST CASH LICENSING PAYMENT FROM ONCOLOGY PRODUCTS PARTNER, TOTALING $546,000 FROM THREE PARTNERS
Reuters · 12/11 11:30
Weekly Report: what happened at ABVC last week (1202-1206)?
Weekly Report · 12/09 11:03
Weekly Report: what happened at ABVC last week (1125-1129)?
Weekly Report · 12/02 11:04
Weekly Report: what happened at ABVC last week (1118-1122)?
Weekly Report · 11/25 10:56
Weekly Report: what happened at ABVC last week (1111-1115)?
Weekly Report · 11/18 10:54
Based on the provided financial report, the title of the article is: "Form 10-Q: Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934" This title indicates that the report is a quarterly report filed by the company with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934.
Press release · 11/14 22:13
ABVC BioPharma GAAP EPS of -$0.02, revenue of $0.38M
Seeking Alpha · 11/14 19:11
*ABVC BioPharma 3Q Rev $389,276 >ABVC3
Dow Jones · 11/14 14:01
*ABVC BioPharma 3Q Loss/Shr 2c >ABVC
Dow Jones · 11/14 14:01
ABVC BIOPHARMA, INC. REPORTS Q3 2024 FINANCIAL RESULTS AND OPERATIONAL MILESTONES
Reuters · 11/14 14:00
More
Webull provides a variety of real-time ABVC stock news. You can receive the latest news about Abvc Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABVC
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.